Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605490686 | ||
| 003 | CHVBK | ||
| 005 | 20210128100506.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-015-0841-4 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-015-0841-4 | ||
| 245 | 0 | 0 | |a Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer |h [Elektronische Daten] |c [Masahiro Inoue, Shin Takahashi, Hiroshi Soeda, Hideki Shimodaira, Mika Watanabe, Koh Miura, Iwao Sasaki, Shunsuke Kato, Chikashi Ishioka] |
| 520 | 3 | |a Background: Comprehensive gene-expression analysis is very useful for classifying specific cancers into subgroups on the basis of their biological characteristics; it is used both prognostically and predictively. The purpose of this study was to classify unresectable advanced or recurrent colorectal cancer (CRC) by gene-expression profiling of formalin-fixed paraffin-embedded tissues and to correlate CRC subgroups with clinicopathological and molecular features and clinical outcomes. Methods: One hundred patients with advanced or recurrent CRC were enrolled. RNA extracted from FFPE tissues was subjected to gene-expression microarray analysis. Results: The patients were stratified into four subgroups (subtypes A1, A2, B1, and B2) by unsupervised hierarchical clustering. By use of principle-components analysis (PCA), the patients were divided into subtypes A and B on the basis of component 1 and into subtypes 1 and 2 on the basis of component 2. Subtype A was significantly enriched among patients without the KRAS mutation and with an earlier clinical stage at diagnosis. With regard to anti-EGFR therapy, progression-free survival (PFS) was better for patients in subtype A without the KRAS mutation than for those with the KRAS mutation (P=0.047). PFS for patients without the KRAS mutation in subtype B was comparable with that for patients with the KRAS mutation (P=0.55). Similar results were observed in a validation set. Conclusion: We found that gene-expression profiles enabled stratification of CRC patients into four subgroups. The efficacy of anti-EGFR therapy was correlated with component 1 from PCA. This comprehensive study may explain the heterogeneity of unresectable advanced or recurrent CRC and could be useful for identifying novel biomarkers for CRC treatment. | |
| 540 | |a Japan Society of Clinical Oncology, 2015 | ||
| 690 | 7 | |a Colorectal cancer |2 nationallicence | |
| 690 | 7 | |a Comprehensive gene-expression analysis |2 nationallicence | |
| 690 | 7 | |a Subtype classification |2 nationallicence | |
| 690 | 7 | |a Anti-EGFR therapy |2 nationallicence | |
| 700 | 1 | |a Inoue |D Masahiro |u Department of Clinical Oncology, Institute of Development, Aging and Cancer Tohoku University, 4-1 Seiryo-machi, Aobaku, 980-8575, Sendai, Japan |4 aut | |
| 700 | 1 | |a Takahashi |D Shin |u Department of Clinical Oncology, Institute of Development, Aging and Cancer Tohoku University, 4-1 Seiryo-machi, Aobaku, 980-8575, Sendai, Japan |4 aut | |
| 700 | 1 | |a Soeda |D Hiroshi |u Department of Clinical Oncology, Institute of Development, Aging and Cancer Tohoku University, 4-1 Seiryo-machi, Aobaku, 980-8575, Sendai, Japan |4 aut | |
| 700 | 1 | |a Shimodaira |D Hideki |u Department of Clinical Oncology, Institute of Development, Aging and Cancer Tohoku University, 4-1 Seiryo-machi, Aobaku, 980-8575, Sendai, Japan |4 aut | |
| 700 | 1 | |a Watanabe |D Mika |u Department of Pathology, Tohoku University Hospital, 1-1 Seiryo-machi, Aobaku, 980-8575, Sendai, Japan |4 aut | |
| 700 | 1 | |a Miura |D Koh |u Department of Gastroenterological Surgery, Tohoku University Hospital, 1-1 Seiryo-machi, Aobaku, 980-8575, Sendai, Japan |4 aut | |
| 700 | 1 | |a Sasaki |D Iwao |u Department of Gastroenterological Surgery, Tohoku University Hospital, 1-1 Seiryo-machi, Aobaku, 980-8575, Sendai, Japan |4 aut | |
| 700 | 1 | |a Kato |D Shunsuke |u Department of Clinical Oncology, Institute of Development, Aging and Cancer Tohoku University, 4-1 Seiryo-machi, Aobaku, 980-8575, Sendai, Japan |4 aut | |
| 700 | 1 | |a Ishioka |D Chikashi |u Department of Clinical Oncology, Institute of Development, Aging and Cancer Tohoku University, 4-1 Seiryo-machi, Aobaku, 980-8575, Sendai, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/6(2015-12-01), 1147-1155 |x 1341-9625 |q 20:6<1147 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-015-0841-4 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-015-0841-4 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Inoue |D Masahiro |u Department of Clinical Oncology, Institute of Development, Aging and Cancer Tohoku University, 4-1 Seiryo-machi, Aobaku, 980-8575, Sendai, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Takahashi |D Shin |u Department of Clinical Oncology, Institute of Development, Aging and Cancer Tohoku University, 4-1 Seiryo-machi, Aobaku, 980-8575, Sendai, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Soeda |D Hiroshi |u Department of Clinical Oncology, Institute of Development, Aging and Cancer Tohoku University, 4-1 Seiryo-machi, Aobaku, 980-8575, Sendai, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Shimodaira |D Hideki |u Department of Clinical Oncology, Institute of Development, Aging and Cancer Tohoku University, 4-1 Seiryo-machi, Aobaku, 980-8575, Sendai, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Watanabe |D Mika |u Department of Pathology, Tohoku University Hospital, 1-1 Seiryo-machi, Aobaku, 980-8575, Sendai, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Miura |D Koh |u Department of Gastroenterological Surgery, Tohoku University Hospital, 1-1 Seiryo-machi, Aobaku, 980-8575, Sendai, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Sasaki |D Iwao |u Department of Gastroenterological Surgery, Tohoku University Hospital, 1-1 Seiryo-machi, Aobaku, 980-8575, Sendai, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kato |D Shunsuke |u Department of Clinical Oncology, Institute of Development, Aging and Cancer Tohoku University, 4-1 Seiryo-machi, Aobaku, 980-8575, Sendai, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ishioka |D Chikashi |u Department of Clinical Oncology, Institute of Development, Aging and Cancer Tohoku University, 4-1 Seiryo-machi, Aobaku, 980-8575, Sendai, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/6(2015-12-01), 1147-1155 |x 1341-9625 |q 20:6<1147 |1 2015 |2 20 |o 10147 | ||